Antiglioma activity of 2,2′:6′,2ʺ-terpyridineplatinum(II) complexes in a rat model—Effects on cellular redox metabolism

作者: Rezvan Ahmadi , Sabine Urig , Marius Hartmann , Burkhard M. Helmke , Sasa Koncarevic

DOI: 10.1016/J.FREERADBIOMED.2005.09.031

关键词:

摘要: Abstract The mammalian thioredoxin system, comprising the selenoenzyme reductase (TrxR) and 12-kDa protein (Trx), is implicated in thiol-mediated antioxidant defense redox regulatory processes including transcriptional control, DNA synthesis, apoptosis. Cell proliferation supported by system can be suppressed TrxR inhibition. In this study, we assessed effects of potent hTrxR inhibitors 4-mercaptopyridine (4′-chloro-2,2′:6′,2ʺ-terpyridine)platinum nitrate (I232N) 2-mercaptopyridine (I252N) on glioblastoma a rat model. These compounds show no or little cross-resistance with cisplatin are thus great clinical interest. Triple intravenous application 25–35 mg/kg led to significant decrease tumor growth as determined magnetic resonance imaging. Metabolic well parameters blood animals were not altered. However, activity was significantly decreased tissue, parameters—including glutathione concentrations, total status, activities different enzymes—showed tissue-specific variations. As indicated apoptotic markers, antitumor I232N mediated induction programmed cell death but rather inhibition intercalation leading cycle arrest.

参考文章(56)
Catherine Rice-Evans, Nicholas J. Miller, TOTAL ANTIOXIDANT STATUS IN PLASMA AND BODY FLUIDS Methods in Enzymology. ,vol. 234, pp. 279- 293 ,(1994) , 10.1016/0076-6879(94)34095-1
K. Becker, B. Krebs, R. H. Schirmer, Protein-chemical standardization of the erythrocyte glutathione reductase activation test (EGRAC test). Application to hypothyroidism. International Journal for Vitamin and Nutrition Research. ,vol. 61, pp. 180- 187 ,(1991)
Eman M. Ali Emadi, Kathryn Fay Tonissen, Francis Michael Clarke, David T. Lincoln, The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Research. ,vol. 23, pp. 2425- 2433 ,(2003)
Junji Yodoi, Hiroki Nanri, Takefumi Ohga, Mayumi Ono, Akira Yokomizo, Morimasa Wada, Michihiko Kuwano, Kimitoshi Kohno, Yoshinari Makino, Takashi Okamoto, Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide Cancer Research. ,vol. 55, pp. 4293- 4296 ,(1995)
Paul Kleihues, David N. Louis, Bernd W. Scheithauer, Lucy B. Rorke, Guido Reifenberger, Peter C. Burger, Webster K. Cavenee, The WHO Classification of Tumors of the Nervous System Journal of Neuropathology and Experimental Neurology. ,vol. 61, pp. 215- 225 ,(2002) , 10.1093/JNEN/61.3.215
Patty A. Kormanik, Marc C. Chamberlain, Practical guidelines for the treatment of malignant gliomas. Western Journal of Medicine. ,vol. 168, pp. 114- 120 ,(1998)
C Herold-Mende, T Andl, C Reisser, A Buttler, D Riede, M M Mueller, H H Steiner, N E Fusenig, Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Laboratory Investigation. ,vol. 79, pp. 1573- 1582 ,(1999)
Allen D. Smith, Catherine A. Guidry, Virginia C. Morris, Orville A. Levander, Aurothioglucose Inhibits Murine Thioredoxin Reductase Activity In Vivo Journal of Nutrition. ,vol. 129, pp. 194- 198 ,(1999) , 10.1093/JN/129.1.194
Katja Becker, Stephan Gromer, R. Heiner Schirmer, Sylke Müller, Thioredoxin reductase as a pathophysiological factor and drug target FEBS Journal. ,vol. 267, pp. 6118- 6125 ,(2000) , 10.1046/J.1432-1327.2000.01703.X